Axitinib-13C-d3 – 1 mg

Brand:
Cayman
CAS:
1261432-00-1
Storage:
-20
UN-No:
De Minimis - 3077 / 9

Axitinib-13C-d3 is intended for use as an internal standard for the quantification of axitinib (Item No. 13813) by GC- or LC-MS. Axitinib (Item No. 13813) is a VEGFR inhibitor (IC50s = 1.2, 0.25, and 0.29 nM for VEGFR1, -2, and -3, respectively).{18372} It also inhibits c-Kit and PDGFRβ (IC50s = 1.7 and 1.6 nM, respectively). It inhibits VEGF-induced migration of and tube formation by human umbilical vein endothelial cells (HUVECs).{57053} Axitinib (1-100 mg/kg) reduces microvessel density, a marker of angiogenesis, and tumor growth in MV522 colon carcinoma, A375 melanoma, SN12C-GFP renal carcinoma, and U87 glioma mouse xenograft models in a dose-dependent manner. Formulations containing axitinib have been used in the treatment of renal cell carcinoma.  

 

Available on backorder

SKU: 26676 - 1 mg Category:

Description

An internal standard for the quantification of axitinib by GC- or LC-MS


Formal name: (E)-N-(methyl-13C-d3)-2-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)benzamide

Synonyms:  AG-013736-13C-d3

Molecular weight: 390.5

CAS: 1261432-00-1

Purity: ≥99% deuterated forms (d1-d3)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|13C||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Kinase Inhibitors|PDGFR Family||Product Type|Biochemicals|Kinase Inhibitors|VEGFR Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Angiogenesis||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling